The control of gene expression is at the core of biological development and homeostasis, and developmental pathways are often disrupted in disease processes. This is particularly true in hepatobiliary disease, as illustrated by the existence of over 20 congenital disorders associated with defects in the differentiation, morphogenesis, and maintenance of the bile ducts. This class includes biliary atresia, of which approximately 1/3rd of cases are associated with a developmental defect of the bile ducts (1, 2). In light of the fact that biliary atresia is the most common indication for pediatric liver transplantation, an understanding of the molecular basis of bile duct development may have a significant impact on human health. In recent years, an unexpected form of gene regulation has been discovered in which small RNA molecules known as microRNAs (miRNA) repress the expression of target genes through RNA interference (reviewed in (3-5)). There are over 500 human miRNAs and these may collectively regulate 20-30% of all genes (6-8). Virtually nothing is known regarding the function of miRNA in liver development and disease. To address this, we have performed the first large-scale study of miRNA expression during mouse liver development (see Preliminary Data), resulting in the identification of hepatic miRNAs whose spatio-temporal expression is suggestive of developmental functions. One of these (miR- 30a) is predominantly expressed in the ductal plate and bile ducts. We have utilized the zebrafish model system as a rapid, preliminary assay to test the function of miR-30a. As shown in the Preliminary Studies, zebrafish miR-30a is critical for the normal development and function of bile ducts. This proposal aims to investigate the biological and molecular function of miR-30a in the mammalian liver.
In Aim 1, we will derive a mouse model of hepatic miR-30a deficiency and we will measure the effects of this deficiency on biliary structure and function.
In Aim 2, we will use this model, a cell culture model, and computational prediction to perform a large-scale survey of miR-30a targets in the liver. The research proposed is significant because it may provide the first demonstration of a requirement for miRNA in liver development and it will significantly add to our limited understanding of the regulatory pathways controlling this biological process. It directly addresses goals of the NIH Action Plan for Liver Research regarding liver development (12). ? Project Narrative This proposal will study a recently-discovered form of gene regulation during the formation of the the [sic] bile ducts within the liver. This will help us to understand the normal development of the liver and the ways in which that process goes awry in a spectrum of diseases associated with malformations of the bile ducts. Those insights can then be applied towards better treatment of diseases of the liver and bile ducts. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Research Grants (R03)
Project #
1R03DK081450-01
Application #
7509250
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Podskalny, Judith M,
Project Start
2008-09-01
Project End
2010-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$82,250
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Cazanave, Sophie; Podtelezhnikov, Alexei; Jensen, Kristian et al. (2017) The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. Sci Rep 7:17193
Oseini, Abdul M; Sanyal, Arun J (2017) Therapies in non-alcoholic steatohepatitis (NASH). Liver Int 37 Suppl 1:97-103
Santhekadur, Prasanna K; Kumar, Divya P; Seneshaw, Mulugeta et al. (2017) The multifaceted role of natriuretic peptides in metabolic syndrome. Biomed Pharmacother 92:826-835
Mota, Manoela; Banini, Bubu A; Cazanave, Sophie C et al. (2016) Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 65:1049-61
Kumar, Divya P; Asgharpour, Amon; Mirshahi, Faridoddin et al. (2016) Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet ? Cells to Promote Glucose Homeostasis. J Biol Chem 291:6626-40
Min, Hae-Ki; Maruyama, Hitoshi; Jang, Byoung Kuk et al. (2016) Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. FASEB J 30:4071-4082
Sanyal, Arun J (2015) Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. Dig Dis 33:426-32
Stewart, Karen E; Haller, Deborah L; Sargeant, Carol et al. (2015) Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int 35:936-43
Pacana, Tommy; Cazanave, Sophie; Verdianelli, Aurora et al. (2015) Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. PLoS One 10:e0136822
Cazanave, S C; Wang, X; Zhou, H et al. (2014) Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis. Cell Death Differ 21:1303-12

Showing the most recent 10 out of 11 publications